AzTrials
AzTrials

Hypertrophic ScarNCT05771623

Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar

A study testing Iontophoresis drug delivery device and Traditional physical therapy in people with Hypertrophic Scar, run by Cairo University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this clinical trial study: is to determine the effect Botulinum toxin type A iontophoresis in hypertrophic scars for post burned patients. The main question is it aims to answer is: Does Botulinum toxin type A iontophoresis may help in minimizing postburn hypertrophic scars? Participants will receive the… Read more about this study

Who is it for?
Ages 20 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Hypertrophic Scar
What is being tested?
Iontophoresis drug delivery device and Traditional physical therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
76 participants
Where
1 siteEgypt
Study dates
1 Aug 2022to Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patient with hypertrophic scar (3-6) months after burn healing.
  • Age range between 20-40 years.
  • Male and female patients will participate in the study.
  • All patients have a postburn hypertrophic scar at different body sites.
  • All patients enrolled on the study will have their informed consent.

Who cannot join

  • Patients with prior medical histories of cardiac arrhythmias.
  • Patients with cardiac pacemakers.
  • Patients with orthopedic implants.
  • Areas of skin with lesions and impaired sensation.
  • During pregnancy and breastfeeding.
  • Patient with diabetes mellitus.
Show all 9Show fewer
  • Patients with a history of hypersensitivity or adverse reactions associated with (BTX_A).
  • Recent BTA administration 6 months before the study.
  • Any subject complaining of psychiatric disorders or neurological disorders such as myasthenia gravis.

Trial locations and contacts

1 site in 1 country.

H M Alnawagy, A lecturer contact

+201032733250

hayammahmoud120@gmail.com

A M Abd El Baky, Professor contact

+201124663339

amalabaky@yahoo.com

Egypt1 site, 1 recruiting
  • Faculty of physical therapy

    Giza, Dokki, 11432

    A M Abd Elbaky, Professor, +201124663339, amalabaky@yahoo.com

    N H Aboelnour, A. Professor, Telephone: 01068904389

    Recruiting

Other trials in Egypt

About this study

The goal of this clinical trial study: is to determine the effect Botulinum toxin type A iontophoresis in hypertrophic scars for post burned patients. The main question is it aims to answer is:

  • Does Botulinum toxin type A iontophoresis may help in minimizing postburn hypertrophic scars?
  • Participants will receive the treatment for 3 months.
  • Assessment will be done before and after treatment.
Read the detailed description
  1. Subjects: Seventy-six Patients from both genders who have post burn hypertrophic scar will participate in this study. Their ages will be ranged 20 to 40 years.
  2. Design of the study:

In this study the patients will be randomly assigned into two equal groups (38 patients for each group):

  1. Group A (Study group): This group includes 38 patients who will receive botulinum toxin type A iontophoresis once monthly for 3 months, in additional to traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.
  2. Group B (Control group): This group includes 38 patients who will receive traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.
  • Equipments: Measurement equipments:
  1. Sonography: It is high-resolution B-image sonogram which allows a good penetration depth of up to 40 mm into the skin and a resolution of around 158 micro m. It has been successfully utilized for objectively measuring pathological scars.
  2. Patient and Observer Scar Assessment Scale (POSAS): It consists of two parts; one for the patient (Patient scale; POSAS Patient) and one for the physician (Observer scale; POSAS Observer). Both contain six items on a 10-point rating scale and an extra category "Overall Opinion". All characteristic features of the pathological scars are covered by the questionnaire: vascularity, pigmentation disorders, relief/texture, thickness, pliability, surface area, pain, and itching/pruritus. The latter items, in particular, concern the well-being of the patients.
  • Sonography:
  • High frequency ultrasound is the most common used technique for scar assessment.
  • The working mechanism is based on refection of sound waves of structures with different acoustic impedances and the analysis of the refection time to determine the depth of the structure.
  • The penetration depth ranges from the upper dermal layers to full-thickness skin and subcutaneous structures, depending on the employed frequency b. Patient and Observer scar Assessment Scale (POSAS):
  • The scar will be rated numerically on a ten-step scale by both the patient and doctor.
  • Six items on the Observer Scale: vascularity, pigmentation, thickness, relief, pliability, and surface area.
  • The Patient Scale consists of pain, itchiness, color, stiffness, thickness, and irregularity of the scar.
  • One of the reasons POSAS was chosen for scar evaluation is because it is the only scar assessment tool to include a component for patients to fill in.
  • Furthermore, its distinctive feature of reflecting subjective symptoms like pain and pruritus and because of its appropriateness for everyday practice.
  • Both sonography and POSAS will be used for assessment of hypertrophic scar pre-treatment and post treatment (after 3 months then after 6 months as follow up).
  • Procedures of iontophoresis drug delivery device: the iontophoresis group will receive botulinum toxin type A iontophoresis using an iontophoretic drug delivery system (Phoresor IIAuto,Model PM850, IOMED.) - Procedures of botulinum toxin type A iontophoresis:
  • Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) will be used.
  • 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) will be administered once a month for a total period of three months.
  • The dose will be adjusted to 2.5 U/cm2 of the lesion.
  • The dose shouldn't exceed 100 units per session.
  • Physical therapy program for both groups: traditional physical therapy (Positioning, Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months
Being tested
Iontophoresis drug delivery device, Traditional physical therapy
Keywords
Hypertrophic scar
Medical subject headings
Cicatrix, Hypertrophic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Iontophoresis drug delivery deviceDevice

    Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.

    The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.

    This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).

  • Traditional physical therapyBehavioural

    Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).

Study groups in NCT05771623
Study groupRoleWhat they receive
Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic ScarExperimentalThe study group includes 38 postburn hypertrophic scar patients l receiving Botox iontophoresis once monthly for 3 months; in addition to their physical therapy program (Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months. Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months. The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.
Receives: Device: Iontophoresis drug delivery device; Behavioral: Traditional physical therapy
Traditional physical therapy for postburn hypertrophic scarActive comparatorThis group includes 38 patients with postburn hypertrophic scar who will receive the traditional PT (deep friction massage, stretching and pressure therapy).
Receives: Behavioral: Traditional physical therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. High resoluton ultrasonography

    High frequency ultrasound is the most common used technique for scar assessment. Its inferior resolution compared to optical equivalents is mitigated by its superior penetration depth allowing thickness analysis, even in severe scar thickening. The working mechanism is based on refection of sound waves of structures with different acoustic impedances and the analysis of the refection time to determine the depth of the structure. The penetration depth ranges from the upper dermal layers to full-thickness skin and subcutaneous structures, depending on the employed frequency.

    Measured: Change of hypertrophic scar thickness from the beginning of treatment to the end of treatment(after 3 months from the beginning of treatment).

  2. Patient and observer scar assessment scale

    The scar will be rated numerically on a ten-step scale by both the patient and doctor on six items: vascularity, pigmentation, thickness, relief, pliability, and surface area on the Observer Scale. The Patient Scale consists of pain, itchiness, color, stiffness, thickness, and irregularity of the scar. Minimal score means good progression and maximum score means the scare is worse.

    Measured: Assessing the change of patient and observer scar assessment scale score from baseline (beginning of treatment) to 3 months after treatment.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Mar 2023
  2. Study start1 Aug 2022
  3. Primary completionDec 2023 (estimated)
  4. Study completionDec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Control group: (38 patients with hypertrophic scar) receive traditional PT for postburn scar. Study group: (38 patients with hypertrophic scar) receive botulinum toxin type a iontophoresis plus traditional PT.
Masking
None (open label)
Enrolment
76 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05771623
Sponsor's protocol ID
P.T.REC/012/003749
Status last verified
Jun 2023
First submitted
14 Feb 2023
Last updated
6 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Iontophoresis drug delivery device and Traditional physical therapy in people with Hypertrophic Scar, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact H M Alnawagy, A lecturer (+201032733250, hayammahmoud120@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

High resoluton ultrasonography (time frame: Change of hypertrophic scar thickness from the beginning of treatment to the end of treatment(after 3 months from the beginning of treatment).). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in